Effects of phased joint intervention on Rho/ROCK expression levels in patients with portal hypertension

Shi,Min; Wei,Jue; Meng,Wen‑Ying; Wang,Na; Wang,Ting; Wang,Yu‑Gang

doi:10.3892/etm.2016.3454

Effects of phased joint intervention on Rho/ROCK expression levels in patients with portal hypertension

Authors:
- Min Shi
- Jue Wei
- Wen‑Ying Meng
- Na Wang
- Ting Wang
- Yu‑Gang Wang
View Affiliations

Affiliations: Department of Gastroenterology, Shanghai Tongren Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200336, P.R. China
Published online on: June 14, 2016 https://doi.org/10.3892/etm.2016.3454
Pages: 1618-1624

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study investigated the effects of phased joint intervention on clinical efficacy and Rho/Rho-associated coil protein kinase (ROCK) expression in patients with portal hypertension complicated by esophageal variceal bleeding (EVB) and hypersplenism. Patients with portal hypertension (n=53) caused by liver cirrhosis complicated by EVB and hypersplenism treated with phased joint intervention were assessed, and portal hemodynamics, blood, liver function, complications, and rebleeding incidence were analyzed. Reverse transcription‑quantitative polymerase chain reaction was used to measure Rho, ROCK1 and ROCK2 mRNA expression levels in peripheral blood mononuclear cells prior to and following phased joint intervention, and western blotting was employed to determine the protein expression levels of Rho, ROCK1, ROCK2, phosphorylated (p) myosin phosphatase target subunit 1 (MYPT1) and total‑MYPT1. All patients underwent an emergency assessment of hemostasis with a 100% success rate. Varicose veins were alleviated, and portal hemodynamics and liver function improved following intervention. Furthermore, preoperative and postoperative expression levels of Rho, ROCK1 and ROCK2 mRNA were higher compared with the control group. Notably, the mRNA expression levels of Rho, ROCK1 and ROCK2 in the postoperative group were significantly lower when compared with the preoperative group. Protein expression levels of Rho, ROCK1, ROCK2 and pMYPT1 in the postoperative group were lower, as compared with the preoperative group. Concentration levels of transforming growth factor‑β1, connective tissue growth factor and platelet‑derived growth factor in peripheral blood were significantly reduced following phased joint intervention. Therefore, the present findings demonstrated that phased joint intervention is able to effectively treat EVB and hypersplenism, and improve liver function. The efficacy of phased joint intervention may be associated with its role in the regulation of the Rho-ROCK signaling pathway.

View Figures

View References

1	Comar KM and Sanyal AJ: Portal hypertensive bleeding. Gastroenterol Clin North Am. 32:1079–1105. 2003. View Article : Google Scholar : PubMed/NCBI
2	Augustin S, González A and Genescà J: Acute esophageal variceal bleeding: Current strategies and new perspectives. World J Hepatol. 2:261–274. 2010. View Article : Google Scholar : PubMed/NCBI
3	Kovalak M, Lake J, Mattek N, Eisen G, Lieberman D and Zaman A: Endoscopic screening for varices in cirrhotic patients: Data from a national endoscopic database. Gastrointest Endosc. 65:82–88. 2007. View Article : Google Scholar : PubMed/NCBI
4	Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, et al: Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 353:2254–2261. 2005. View Article : Google Scholar : PubMed/NCBI
5	Merli M, Nicolini G, Angeloni S, Rinaldi V, De Santis A, Merkel C, Attili AF and Riggio O: Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol. 38:266–272. 2003. View Article : Google Scholar : PubMed/NCBI
6	D'Amico G, Pagliaro L and Bosch J: Pharmacological treatment of portal hypertension: An evidence-based approach. Semin Liver Dis. 19:475–505. 1999. View Article : Google Scholar : PubMed/NCBI
7	Bosch J and García-Pagán JC: Prevention of variceal rebleeding. Lancet. 361:952–954. 2003. View Article : Google Scholar : PubMed/NCBI
8	de Franchis R: Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 43:167–176. 2005. View Article : Google Scholar : PubMed/NCBI
9	Lunderquist A and Vang J: Sclerosing injection of esophageal varices through transhepatic selective catheterization of the gastric coronary vein. A preliminary report. Acta Radiol Diagn (Stockh). 15:546–550. 1974.PubMed/NCBI
10	Benner KG, Keeffe EB, Keller FS and Rösch J: Clinical outcome after percutaneous transhepatic obliteration of esophageal varices. Gastroenterology. 85:146–153. 1983.PubMed/NCBI
11	Chikamori F, Kuniyoshi N, Shibuya S and Takase Y: Correlation between endoscopic and angiographic findings in patients with esophageal and isolated gastric varices. Dig Surg. 18:176–181. 2001. View Article : Google Scholar : PubMed/NCBI
12	L'Herminé C, Chastanet P, Delemazure O, Bonnière PL, Durieu JP and Paris JC: Percutaneous transhepatic embolization of gastroesophageal varices: Results in 400 patients. AJR Am J Roentgenol. 152:755–760. 1989. View Article : Google Scholar : PubMed/NCBI
13	Koconis KG, Singh H and Soares G: Partial splenic embolization in the treatment of patients with portal hypertension: A review of the english language literature. J Vasc Interv Radiol. 18:463–481. 2007. View Article : Google Scholar : PubMed/NCBI
14	Sakata R, Ueno T, Nakamura T, Ueno H and Sata M: Mechanical stretch induces TGF-beta synthesis in hepatic stellate cells. Eur J Clin Invest. 34:129–136. 2004. View Article : Google Scholar : PubMed/NCBI
15	Okada Y, Tsuzuki Y, Hokari R, Miyazaki J, Matsuzaki K, Mataki N, Komoto S, Watanabe C, Kawaguchi A, Nagao S, et al: Pressure loading and ethanol exposure differentially modulate rat hepatic stellate cell activation. J Cell Physiol. 215:472–480. 2008. View Article : Google Scholar : PubMed/NCBI
16	Wang Y, Dong J, Meng W, Ma J, Wang N, Wei J and Shi M: Effects of phased joint intervention on IL-35 and IL-17 expression levels in patients with portal hypertension. Int J Mol Med. 33:1131–1139. 2014.PubMed/NCBI
17	Tangkijvanich P, Tam SP and Yee HF Jr: Wound-induced migration of rat hepatic stellate cells is modulated by endothelin-1 through rho-kinase-mediated alterations in the acto-myosin cytoskeleton. Hepatology. 33:74–80. 2001. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Sun A, Shi YJ, Xu ZD, Tian XG, Hu JH, Wang GC and Zhang CQ: MDCT angiography to evaluate the therapeutic effect of PTVE for esophageal varices. World J Gastroenterol. 19:1563–1571. 2013. View Article : Google Scholar : PubMed/NCBI
20	Hadduck TA and McWilliams JP: Partial splenic artery embolization in cirrhotic patients. World J Radiol. 6:160–168. 2014. View Article : Google Scholar : PubMed/NCBI
21	Sangro B, Bilbao I, Herrero I, Corella C, Longo J, Beloqui O, Ruiz J, Zozaya JM, Quiroga J and Prieto J: Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology. 18:309–314. 1993. View Article : Google Scholar : PubMed/NCBI
22	Pålsson B, Hallén M, Forsberg AM and Alwmark A: Partial splenic embolization: Long-term outcome. Langenbecks Arch Surg. 387:421–426. 2003.PubMed/NCBI
23	Tajiri T, Onda M, Yoshida H, Mamada Y, Taniai N and Kumazaki T: Long-term hematological and biochemical effects of partial splenic embolization in hepatic cirrhosis. Hepatogastroenterology. 49:1445–1448. 2002.PubMed/NCBI
24	Wang Y, Gao J, Zhang D, Zhang J, Ma J and Jiang H: New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol. 53:132–144. 2010. View Article : Google Scholar : PubMed/NCBI
25	Parsons CJ, Bradford BU, Pan CQ, Cheung E, Schauer M, Knorr A, Krebs B, Kraft S, Zahn S, Brocks B, et al: Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology. 40:1106–1115. 2004. View Article : Google Scholar : PubMed/NCBI
26	Pinzani M: Hepatic stellate (ITO) cells: Expanding roles for a liver-specific pericyte. J Hepatol. 22:700–706. 1995. View Article : Google Scholar : PubMed/NCBI
27	Pinzani M, Failli P, Ruocco C, Casini A, Milani S, Baldi E, Giotti A and Gentilini P: Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest. 90:642–646. 1992. View Article : Google Scholar : PubMed/NCBI
28	Thoen LF, Guimarães EL, Dollé L, Mannaerts I, Najimi M, Sokal E and van Grunsven LA: A role for autophagy during hepatic stellate cell activation. J Hepatol. 55:1353–1360. 2011. View Article : Google Scholar : PubMed/NCBI
29	Brown JH, Del Re DP and Sussman MA: The Rac and Rho hall of fame: A decade of hypertrophic signaling hits. Circ Res. 98:730–742. 2006. View Article : Google Scholar : PubMed/NCBI
30	Hennenberg M, Biecker E, Trebicka J, Jochem K, Zhou Q, Schmidt M, Jakobs KH, Sauerbruch T and Heller J: Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology. 130:838–854. 2006. View Article : Google Scholar : PubMed/NCBI
31	Riento K, Guasch RM, Garg R, Jin B and Ridley AJ: RhoE binds to ROCK I and inhibits downstream signaling. Mol Cell Biol. 23:4219–4229. 2003. View Article : Google Scholar : PubMed/NCBI
32	Murata T, Arii S, Mori A and Imamura M: Therapeutic significance of y-27632, a Rho-kinase inhibitor, on the established liver fibrosis. J Surg Res. 114:64–71. 2003. View Article : Google Scholar : PubMed/NCBI
33	Klein S, Van Beuge MM, Granzow M, Beljaars L, Schierwagen R, Kilic S, Heidari I, Huss S, Sauerbruch T, Poelstra K and Trebicka J: HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. J Hepatol. 57:1220–1227. 2012. View Article : Google Scholar : PubMed/NCBI
34	Kawada N, Seki S, Kuroki T and Kaneda K: Rock inhibitor y-27632 attenuates stellate cell contraction and portal pressure increase induced by endothelin-1. Biochem Biophys Res Commun. 266:296–300. 1999. View Article : Google Scholar : PubMed/NCBI
35	Bissell DM, Roulot D and George J: Transforming growth factor beta and the liver. Hepatology. 34:859–867. 2001. View Article : Google Scholar : PubMed/NCBI
36	Boettner B and Van Aelst L: The role of Rho GTPases in disease development. Gene. 286:155–174. 2002. View Article : Google Scholar : PubMed/NCBI
37	Hahn A, Heusinger-Ribeiro J, Lanz T, Zenkel S and Goppelt-Struebe M: Induction of connective tissue growth factor by activation of heptahelical receptors. Modulation by Rho proteins and the actin cytoskeleton. J Biol Chem. 275:37429–37435. 2000. View Article : Google Scholar : PubMed/NCBI
38	Li C and Xu Q: Mechanical stress-initiated signal transductions in vascular smooth muscle cells. Cell Signal. 12:435–445. 2000. View Article : Google Scholar : PubMed/NCBI